

Chiara Simeoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9228479/publications.pdf>

Version: 2024-02-01

38
papers

1,655
citations

411340

20
h-index

388640

36
g-index

42
all docs

42
docs citations

42
times ranked

2245
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction: a multicentre, double-blind, randomized, placebo-controlled clinical trial. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 941-961.	1.8	6
2	Bone metabolism in patients with type 1 neurofibromatosis: key role of sun exposure and physical activity. <i>Scientific Reports</i> , 2022, 12, 4368.	1.6	6
3	Vitamin D Reverts the Exosome-Mediated Transfer of Cancer Resistance to the mTOR Inhibitor Everolimus in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 874091.	1.3	2
4	Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1869-1878.	1.8	6
5	Characterization with hybrid imaging of cystic pheochromocytomas: correlation with pathology. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 862-869.	1.1	5
6	Characterization of Atypical Pheochromocytomas with Correlative MRI and Planar/Hybrid Radionuclide Imaging: A Preliminary Study. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 9666.	1.3	4
7	The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 57-73.	1.8	13
8	Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 683-696.	1.8	34
9	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 648.	1.5	72
10	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1141-1147.	1.8	103
11	Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 99.	1.2	13
12	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	1.0	31
13	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019, 9, 11695.	1.6	14
14	Long-Term Complications of Hypercortisolism. , 2019, , 341-359.		1
15	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018, , 325-374.	0.1	1
16	Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 173-185.	5.5	155
17	Physiopathology, Diagnosis, and Treatment of Hypercortisolism. <i>Endocrinology</i> , 2018, , 1-50.	0.1	0
18	ACTH-Secreting Pituitary Tumors. , 2018, , 248-260.		0

#	ARTICLE	IF	CITATIONS
19	The degree of urinary hypercortisolism is not correlated with the severity of cushingâ€™s syndrome. <i>Endocrine</i> , 2017, 55, 564-572.	1.1	32
20	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017, 55, 872-884.	1.1	36
21	Cushingâ€™s disease: the burden of illness. <i>Endocrine</i> , 2017, 56, 10-18.	1.1	136
22	Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. <i>Pituitary</i> , 2017, 20, 46-62.	1.6	162
23	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017, 158, 1527-1532.	1.4	13
24	Pituitary magnetic resonance imaging in Cushingâ€™s disease. <i>Endocrine</i> , 2017, 55, 691-696.	1.1	54
25	Influence of Bisphenol A on Type 2 Diabetes Mellitus. <i>International Journal of Environmental Research and Public Health</i> , 2016, 13, 989.	1.2	72
26	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016, 46, 54-65.	1.0	31
27	Is mortality in Cushing's disease reversible with remission?. <i>Lancet Diabetes and Endocrinology</i> , the, 2016, 4, 551-552.	5.5	2
28	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 9718-9731.	0.8	19
29	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129.	1.4	124
30	The treatment with pasireotide in Cushingâ€™s disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015, 50, 725-740.	1.1	40
31	Evaluation of the retinal nerve fibre layer and ganglion cell complex thickness in pituitary macroadenomas without optic chiasmal compression. <i>Eye</i> , 2015, 29, 797-802.	1.1	42
32	Is diabetes in Cushing's syndrome only a consequence of hypercortisolism?. <i>European Journal of Endocrinology</i> , 2014, 170, 311-319.	1.9	60
33	The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions. <i>Current Molecular Pharmacology</i> , 2014, 6, 149-155.	0.7	8
34	Pasireotide for the treatment of Cushing's disease. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 557-567.	0.5	2
35	Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. <i>European Journal of Endocrinology</i> , 2013, 169, 359-366.	1.9	63
36	Effect of Cabergoline on Metabolism in Prolactinomas. <i>Neuroendocrinology</i> , 2013, 98, 299-310.	1.2	60

#	ARTICLE	IF	CITATIONS
37	Pathophysiology of Diabetes Mellitus in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 77-81.	1.2	146
38	Cardiovascular Disease in Cushing's Syndrome: Heart versus Vasculature. <i>Neuroendocrinology</i> , 2010, 92, 50-54.	1.2	86